BPC-157 Capsules, Oral Research Formats
BPC-157 in an oral capsule presentation for laboratory research. This page covers what the oral format is, what the per-oral literature on plain BPC-157 in rats does and does not establish, and how the choice of salt form changes the net peptide content of the material you receive. No dosing guidance is given anywhere on this site.
This research format is not currently listed. Contact the lab desk for availability.
Looking for the salt-form technical detail, the origin of the widely repeated stability and bioavailability numbers, or the term pentadeca arginate? Read the BPC-157 arginate (PDA) source-tracing page.
What a BPC-157 capsule is
BPC-157 is a synthetic pentadecapeptide, sequence GEPPPGKPADDAGLV, corresponding to a partial sequence of a protein isolated from human gastric juice. As a free peptide its molecular weight is 1419.53 g/mol. A capsule presentation is simply that peptide, as a salt, filled into a dry capsule shell rather than supplied as a lyophilised powder in a sealed vial.
The format matters for study design rather than convenience alone. A large share of the published BPC-157 work used per-oral administration, typically as peptide dissolved in the drinking water of rats, and a capsule gives an enteral arm without reconstitution, bacteriostatic water, or injection equipment. Where a protocol calls for a parenteral comparator, the injectable presentation is a separate material.
What a capsule does not do is answer the absorption question. Placing a peptide in the gut lumen is not the same as delivering it to systemic circulation, and no formulation choice on this page should be read as a claim that it does.
The per-oral literature on plain BPC-157
The following studies administered unmodified BPC-157 by the per-oral route, in rodents, and are the primary basis for the existence of an oral research format at all. Each describes what was measured in animals; none is an instruction, and none involves humans.
Ilic et al., 2011
PMID 21295044In rats, BPC-157 given per-orally in drinking water was assessed against diclofenac-induced hepatic lesion endpoints. The study reports outcomes in a rat model only.
Cerovecki et al., 2010
PMID 20225319In rats, per-oral and parenteral BPC-157 were compared in a transected medial collateral ligament model, with healing and biomechanical endpoints recorded in the animals.
Sever et al., 2009
PMID 19093208In rats, BPC-157 administered per-orally in drinking water was examined in a transected Achilles tendon model, again with animal healing endpoints.
Skorak et al., 2025
PMID 39861766A recent review of the BPC-157 literature, restating the preclinical record and the limits of the evidence base rather than adding new in vivo data.
What that literature does not establish
- The findings are in rats, by the per-oral route. No result above transfers to humans, and nothing in this body of work was designed to.
- The great majority of the per-oral work originates with a single primary research group. Independent replication across laboratories is thin.
- None of these studies measured plasma pharmacokinetics after oral administration. There is no published absolute oral bioavailability figure for BPC-157 in any species.
- There are no human randomised controlled trials of BPC-157 by any route or in any salt form.
- Effect in a model is not evidence of an outcome in a person, and no such outcome is claimed here.
The human evidence, stated honestly
Vasireddi et al., 2025, a systematic review (PMID 40756949), screened 544 articles and included 36. Of the 36 included records, 35 were preclinical. One was clinical: a retrospective series of 12 patients. The review reported that no clinical safety data were available.
That is the whole human record as of that review. It is the reason every biological statement on this site carries a species and a route, and the reason Peptx makes no therapeutic claim for any BPC-157 presentation.
The salt-form question, in short
Oral BPC-157 is sold as either an acetate salt or an arginate salt, the latter also marketed as pentadeca arginate or PDA. The peptide itself is identical in both. The counter-ion differs, which changes molecular weight and therefore the proportion of each milligram of material that is actually BPC-157. Salt choice is also the basis of widely repeated claims about gastric stability and oral bioavailability.
Those claims have a single traceable origin, and one of the two most-quoted numbers does not appear in that source at all. Rather than repeat them here, we traced each figure back to its primary document, reproduced the underlying tables, and set them against the only measured pharmacokinetic data that exists for this peptide.
Where the 90% bioavailability and 1,000x stability numbers came from
Full source tracing: the patent, the actual gastric-juice table, the net peptide content arithmetic, and the intramuscular pharmacokinetic study that calibrates all of it.
BPC-157 arginate (pentadeca arginate / PDA), sources tracedHandling, storage and documentation
Long term storage
Store sealed containers at 2 to 8 °C, protected from light and moisture, for the printed shelf life.
In use storage
Once opened, keep tightly closed at 2 to 8 °C. Peptide salts are hygroscopic and ambient humidity drives mass gain.
Handling
Handle with clean dry forceps. Record batch number against every experimental record.
Net peptide content
Read net peptide content from the certificate of analysis where one is available, rather than from nominal label mass, since salt stoichiometry and residual water vary batch to batch.
Frequently asked questions
What are BPC-157 capsules as a research format?+
An oral presentation of the pentadecapeptide BPC-157 (sequence GEPPPGKPADDAGLV) supplied as a dry capsule rather than a lyophilised powder for reconstitution. The format exists because a substantial part of the published BPC-157 literature used per-oral administration in rodent models, so an enteral arm is often required for study design parity. Supplied strictly as a laboratory research material.
What does the oral BPC-157 literature actually establish?+
Per-oral administration of plain BPC-157 in drinking water produced measurable effects in rat models across several published studies from a single primary research group. That establishes that an orally administered rat receives a biologically active exposure in those models. It does not establish plasma pharmacokinetics, absolute oral bioavailability, or any finding in humans.
Is there human evidence for BPC-157?+
A 2025 systematic review (PMID 40756949) screened 544 articles and included 36. Of those, 35 were preclinical and one was clinical, a retrospective series of 12 patients. The review reported no clinical safety data. Any statement about human outcomes is therefore unsupported by the current published record.
Does the salt form of an oral BPC-157 capsule matter?+
The peptide is identical across salt forms; only the counter-ion differs. Salt choice changes molecular weight and therefore net peptide content per milligram of material, and it is claimed to change gastric stability. The stability claim traces to a single commercial patent and has not been independently replicated. The arginate page on this site traces each figure to its primary source.
Are Peptx capsules tested?+
Manufacturer HPLC and MS are run at source, with selective third-party QC pulls. Independent verification at an accredited ISO 17025 laboratory is supported and encouraged. Net peptide content, which varies with salt stoichiometry and residual water, should be read from the certificate of analysis where one is available.
Are these capsules for human consumption?+
No. They are supplied for laboratory research use only and are not licensed by the MHRA, FDA, EMA or any other medicines regulator. They are not approved or intended for human or veterinary consumption.
References and further reading
Related pages
Strictly for laboratory research. Not for human consumption. No therapeutic or medical claims are made.